Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial.
Alotaibi F, Alharbi NK, Rosen LB, Asiri AY, Assiri AM, Balkhy HH, Al Jeraisy M, Mandourah Y, AlJohani S, Al Harbi S, Jokhdar HAA, Deeb AM, Memish ZA, Jose J, Ghazal S, Al Faraj S, Al Mekhlafi GA, Sherbeeni NM, Elzein FE, AlMutairi BM, Al-Dawood A, Abdullah ML, Barhoumi T, Alenazi MW, Almasood A, Holland SM, Arabi YM; Saudi Critical Care Trials Group. Alotaibi F, et al. Among authors: alenazi mw. Influenza Other Respir Viruses. 2023 Mar 21;17(3):e13116. doi: 10.1111/irv.13116. eCollection 2023 Mar. Influenza Other Respir Viruses. 2023. PMID: 36960162 Free PMC article. Clinical Trial.
Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia.
Alharbi NK, Alghnam S, Algaissi A, Albalawi H, Alenazi MW, Albargawi AM, Alharbi AG, Alhazmi A, Al Qarni A, Alfarhan A, Zowawi HM, Alhatmi H, Alghamdi J, Alroqi F, Batarfi K, Arabi YM, Hashem AM, Bosaeed M, Aldibasi O. Alharbi NK, et al. Among authors: alenazi mw. J Infect Public Health. 2021 Jul;14(7):832-838. doi: 10.1016/j.jiph.2021.04.006. Epub 2021 Apr 24. J Infect Public Health. 2021. PMID: 34118732 Free PMC article.
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels.
Alharbi NK, Aljamaan F, Aljami HA, Alenazi MW, Albalawi H, Almasoud A, Alharthi FJ, Azhar EI, Barhoumi T, Bosaeed M, Gilbert SC, Hashem AM. Alharbi NK, et al. Among authors: alenazi mw. Vaccines (Basel). 2022 Aug 17;10(8):1330. doi: 10.3390/vaccines10081330. Vaccines (Basel). 2022. PMID: 36016218 Free PMC article.
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
Bosaeed M, Balkhy HH, Almaziad S, Aljami HA, Alhatmi H, Alanazi H, Alahmadi M, Jawhary A, Alenazi MW, Almasoud A, Alanazi R, Bittaye M, Aboagye J, Albaalharith N, Batawi S, Folegatti P, Ramos Lopez F, Ewer K, Almoaikel K, Aljeraisy M, Alothman A, Gilbert SC, Khalaf Alharbi N. Bosaeed M, et al. Among authors: alenazi mw. Lancet Microbe. 2022 Jan;3(1):e11-e20. doi: 10.1016/S2666-5247(21)00193-2. Epub 2021 Nov 3. Lancet Microbe. 2022. PMID: 34751259 Free PMC article. Clinical Trial.